Skip to Content

Do you allow analytics?

We use analytics tools to understand how people use the site. They're optional: if you decline, the site works the same, no analytics cookies are set and Google gets only a cookieless, anonymous count signal. The site's own daily visitor count, which sets no cookie and stores no IP address, runs either way. Your votes are saved either way; the details are in the privacy policy.

Election Day is in 17 days. See every seat on the ballot →

Health, U.S. House

Swipe Bills

House Bill

Should the House through the programs that support ALS drug research and development?

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 (H.R. 8205)

Programs funding research on ALS and other neurodegenerative disease treatments would continue through FY2031, with added safety reporting and a new plan.

  • Reauthorizes grants for research on investigational ALS drugs for people not eligible for clinical trials
  • Reauthorizes FDA grants for developing therapies for ALS and other neurodegenerative diseases
  • Reauthorizes the FDA and NIH Public-Private Partnership for treatment development and regulatory review

House Health Bills

383 bills

How This Page Was Made

Bills, sponsors and roll call results come from Congress.gov, the House Clerk and Senate.gov. Summaries are written with AI from the Congressional Research Service (CRS) summary and checked against it. Votes on this site are users’ opinions, not a poll. Built by CDR Technology Foundation, Inc.. Methodology →